Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aestus licenses rights to Astellas' FK614 for pain

Executive Summary

Aestus Therapeutics Inc. (neurological diseases) has licensed exclusive global rights to Astellas Pharma Inc.'s FK614 (renamed ATx08001), a diabetes drug candidate that Aestus found has implication in pain, including post-herpetic neuralgia (PHN).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies